Avidity Biosciences Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
391
- Stock Symbol
-
RNA
- Share Price
-
$28.52
- (As of Monday Closing)
Avidity Biosciences General Information
Description
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Contact Information
Website
www.aviditybiosciences.comCorporate Office
- 10578 Science Center Drive
- Suite 125
- San Diego, CA 92121
- United States
Corporate Office
- 10578 Science Center Drive
- Suite 125
- San Diego, CA 92121
- United States
Avidity Biosciences Stock Performance
As of 21-Apr-2025, Avidity Biosciences’s stock price is $28.52. Its current market cap is $3.43B with 120M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $28.52 | $26.66 | $21.51 - $56.00 | $3.43B | 120M | 1.52M | -$2.89 |
Avidity Biosciences Financials Summary
As of 31-Dec-2024, Avidity Biosciences has a trailing 12-month revenue of $10.9M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,888,523 | 1,888,523 | 184,546 | 1,120,472 |
| Revenue | 10,897 | 10,897 | 9,560 | 9,224 |
| EBITDA | (376,408) | (376,408) | (234,091) | (177,583) |
| Net Income | (322,302) | (322,302) | (212,220) | (173,995) |
| Total Assets | 1,563,895 | 1,563,895 | 628,555 | 638,800 |
| Total Debt | 6,801 | 6,801 | 9,852 | 10,687 |
Avidity Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Avidity Biosciences Comparisons
Industry
Financing
Details
Avidity Biosciences Competitors (43)
One of Avidity Biosciences’s 43 competitors is Dyne Therapeutics, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dyne Therapeutics | Formerly VC-backed | Waltham, MA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany | ||||
| CureVac | Formerly VC-backed | Tubingen, Germany | ||||
| Bicycle Therapeutics | Formerly VC-backed | Cambridge, United Kingdom | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland |
Avidity Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Avidity Biosciences Patents
Avidity Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250121085-A1 | Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 45 skipping | Pending | 02-Oct-2023 | ||
| US-20250032622-A1 | Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates | Pending | 30-Jun-2023 | ||
| US-20250108120-A1 | Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates | Pending | 27-Jun-2023 | ||
| US-20230364256-A1 | Antibody oligonucleotide conjugate compositions and methods of inducing dmd exon 44 skipping | Active | 05-Apr-2022 | ||
| US-12071621-B2 | Anti-transferrin receptor antibody-pmo conjugates for inducing dmd exon 44 skipping | Active | 05-Apr-2022 | A61K47/6849 |
Avidity Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Avidity Biosciences ESG
Risk Overview
Risk Rating
Updated April, 01, 2025
34.79 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Biotechnology
Subindustry
of 371
Rank
Percentile
Avidity Biosciences FAQs
-
When was Avidity Biosciences founded?
Avidity Biosciences was founded in 2012.
-
Where is Avidity Biosciences headquartered?
Avidity Biosciences is headquartered in San Diego, CA.
-
What is the size of Avidity Biosciences?
Avidity Biosciences has 391 total employees.
-
What industry is Avidity Biosciences in?
Avidity Biosciences’s primary industry is Drug Discovery.
-
Is Avidity Biosciences a private or public company?
Avidity Biosciences is a Public company.
-
What is Avidity Biosciences’s stock symbol?
The ticker symbol for Avidity Biosciences is RNA.
-
What is the current stock price of Avidity Biosciences?
As of 21-Apr-2025 the stock price of Avidity Biosciences is $28.52.
-
What is the current market cap of Avidity Biosciences?
The current market capitalization of Avidity Biosciences is $3.43B.
-
What is Avidity Biosciences’s current revenue?
The trailing twelve month revenue for Avidity Biosciences is $10.9M.
-
Who are Avidity Biosciences’s competitors?
Dyne Therapeutics, BioNTech, CureVac, Bicycle Therapeutics, and CRISPR Therapeutics are some of the 43 competitors of Avidity Biosciences.
-
What is Avidity Biosciences’s annual earnings per share (EPS)?
Avidity Biosciences’s EPS for 12 months was -$2.89.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
